Cingulate Inc
CINGW0.100USD
-0.019-16.52%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Cingulate Inc Unternehmen
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Unternehmensinformationen
BörsenkürzelCINGW
Name des UnternehmensCingulate Inc
IPO-datumOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse1901 W. 47Th Place
StadtKANSAS CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl66205
Telefon19139422300
Websitehttps://www.cingulate.com/
BörsenkürzelCINGW
IPO-datumOct 07, 2021
CEODr. Shane J. Schaffer, Pharm.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionärstypen
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
12
238.84K
0.00%
-824.25K
2025Q1
12
238.84K
0.00%
-824.25K
2024Q4
11
230.16K
0.00%
-848.35K
2024Q3
11
526.73K
0.00%
-559.74K
2024Q2
11
1.54M
0.00%
-29.99K
2024Q1
10
1.52M
0.00%
-577.42K
2023Q4
10
2.04M
0.00%
-3.83K
2023Q3
9
2.05M
0.00%
-52.84K
2023Q2
9
2.10M
0.00%
-175.37K
2023Q1
9
2.28M
0.00%
-7.12K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hudson Bay Capital Management LP
210.80K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
12.58K
0%
-2.08K
-14.17%
Mar 31, 2025
GoalVest Advisory, LLC
3.00K
0%
--
--
Mar 31, 2025
Armistice Capital LLC
--
0%
-1.71K
-100.00%
Mar 31, 2025
Altium Capital Management LP
--
0%
-270.00K
-100.00%
Dec 31, 2024
Lynwood Capital Management Inc.
--
0%
-50.00K
-100.00%
Dec 31, 2023
Sabby Management, LLC
--
0%
-458.52K
-100.00%
Sep 30, 2024
Warberg Asset Management LLC
--
0%
-43.16K
-100.00%
Sep 30, 2024
Virtu Americas LLC
--
0%
-11.16K
-100.00%
Dec 31, 2024
BofA Global Research (US)
--
0%
-100.00
-100.00%
Sep 30, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
